Temozolomide is an alkylating agent indicated for the treatment of some brain cancers; as a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme.
Tocilizumab is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of:
Rheumatoid arthritis: moderate to severe rheumatoid arthritis, in combination with the methotrexate, if other drugs like disease-modifying antirheumatic drugs (DMARDs) and TNF alpha blockers have proven to be ineffective or were not tolerated.
Systemic juvenile idiopathic arthritis: for treating systemic juvenile idiopathic arthritis is similar to RA treatment: tocilizumab is combined with the methotrexate unless the latter is not tolerated.
Castleman’s disease: for treatment of a rare benign tumor of B cells.
Neuromyelitis optica: effective in otherwise refractory neuromyelitis optica (NMO, Devic’s disease).
Giant cell arteritis: for giant cell (temporal) arteritis.
Cytokine release syndrome: for cytokine release syndrome, a kind of side effect of CAR-T cell therapies.
The drug is administered by monthly intravenous infusions. An infusion takes about an hour.
Most common adverse reactions include headache, upper respiratory tract infections, nasopharyngitis, hypertension, increased ALT and injection site reactions.
Care should be exercised in the handling of ACTEMRA. ACTEMRA injection should not be opened or crushed. Vials and syringes should be protected from light by storage in the original package until time of use, and keep syringes dry. Store permitted between 2ºC to 8ºC (36°F to 46°F). Do not freeze.
The active ingredient in the medicine is Tocilizumab, and the inactive ingredients are polysorbate 80, L-histidine and L-histidine monohydrochloride, L-arginine, and L-arginine hydrochloride, L-methionine, and water for injection.
Yes, atlizumab is an immunosuppressive drug.
Dizziness, various infections, as well as reactions of the skin and mucosae like mild rashes, gastritis and mouth ulcer are the less common tocilizumab side effects.
In June 2005, this medicine was approved in Japan for treating Castleman’s disease.
In January 2009, this medicine was approved by the EMA (European Medicines Agency) named as RoActemra for treating rheumatoid arthritis.
Yes, the US FDA approved this medication as Actemra, for treating rheumatoid arthritis.
In case of an overdose of Tocilizumab, severe reactions were experienced by patients. If one takes an overdose of the medicine, consult the doctor immediately and keep the patient under observation.
Patients can simply fill the order form or can send mail at email@example.com. Patient can also send WhatsApp message to +91 8130290915. We will reply ASAP with the details of Pricing and procedure.
Note:- The order will be confirmed only after the receipt of Valid prescription of Clinician
Store the medicine at the temperature of 2ºC to 8ºC (36°F to 46°F).
Do not freeze the medicine.
All Trademarks and Brands that appear on the website belong to their respective owners and Ikris Pharma Network does not lay any claim on them, we only provide Information. Tocilizumab is a pharmaceutical drug that legally requires a medical prescription to be dispensed.
Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.